Summit Therapeutics Inc. — Director's Dealing 2025

Jan 7, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Summit Therapeutics Inc. (SMMT)
CIK: 0001599298
Period of Report: 2025-01-02

Reporting Person: DUGGAN ROBERT W (Director, Co-Chief Executive Officer, 10% Owner)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-01-02	Stock Option (right to buy)	$18.35	A	10724	Acquired	2035-01-02	Common Stock (10724)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	551695096	Direct
Common Stock	31000	Indirect
Common Stock	10199776	Indirect
Common Stock	25457666	Indirect
Common Stock	50000	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$3.71	2030-11-11	Common Stock (203323)	203323	Indirect
Stock Option (right to buy)	$4.40	2030-11-22	Common Stock (2400000)	2400000	Indirect
Stock Option (right to buy)	$4.75	2031-12-15	Common Stock (15000)	15000	Indirect
Stock Option (right to buy)	$1.68	2033-10-13	Common Stock (11988198)	11988198	Indirect
Performance Stock Option (right to buy)	$1.06	2032-06-28	Common Stock (260000)	260000	Indirect
Performance Stock Option (right to buy)	$1.29	2032-09-09	Common Stock (100000)	100000	Indirect
Performance Stock Option (right to buy)	$1.68	2033-10-13	Common Stock (2397640)	2397640	Indirect

Footnotes

F1: The Reporting Person acquired beneficial ownership of these securities upon his marriage to the beneficial owner of the securities on December 18, 2024.

F2: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.

F3: The option was granted on January 2, 2025. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 following election, subject to the reporting person remaining as a non-salaried director on each such vesting date.

F4: The option was issued to the reporting person pursuant to the Director Retainer Option Election Plan of issuer in lieu of retainer fees of $98,400.

F5: The option was granted to the Reporting Person's spouse on November 11, 2020 pursuant to the Issuer's Stock Incentive Plan, and are fully vested.

F6: The option was granted to the Reporting Person's spouse on November 22, 2020 pursuant to the Issuer's Stock Incentive Plan. The shares underlying the option are fully vested.

F7: The option was granted to the Reporting Person's spouse on December 15, 2021. The shares underlying the option are fully vested.

F8: The option was granted to the Reporting Person's spouse on October 13, 2023. The shares underlying the option shall vest in four equal annual installments, with the first such installment occurring on October 13, 2024. Note this does not include an additional 11,988,198 options which were granted to the Reporting Person's spouse on October 13, 2023 and are subject to the satisfaction of performance conditions based on market capitalization and revenue targets.

F9: These performance-based stock options vested on August 23, 2024, upon the attainment of the satisfaction of certain financial performance objectives. Note this does not include an additional 1,040,000 shares underlying options which were granted to the Reporting Person's spouse on June 28, 2022, that remain subject to the satisfaction of performance conditions.

F10: These performance-based stock options vested on August 23, 2024, upon the attainment of the satisfaction of certain financial performance objectives. Note this does not include an additional 400,000 shares underlying options which were granted to the Reporting Person's spouse on September 9, 2022 that remain subject to the satisfaction of performance conditions.

F11: These performance-based stock options vested on August 23, 2024, upon the attainment of the satisfaction of certain financial performance objectives. Note this does not include an additional 9,590,558 shares underlying options which were granted to the Reporting Person's spouse on October 13, 2023 that remain subject to the satisfaction of performance conditions.